Detection of IL-17A-producing peripheral blood monocytes in Langerhans cell histiocytosis patients

Detection of IL-17A-producing peripheral blood monocytes in Langerhans cell histiocytosis patients

Copyright © 2014 Elsevier Inc. All rights reserved.

Détails bibliographiques
Publié dans:Clinical immunology (Orlando, Fla.). - 1999. - 153(2014), 1 vom: 05. Juli, Seite 112-22
Auteur principal: Lourda, Magda (Auteur)
Autres auteurs: Olsson-Åkefeldt, Selma, Gavhed, Désirée, Björnfot, Sofia, Clausen, Niels, Hjalmars, Ulf, Sabel, Magnus, Tazi, Abdellatif, Aricò, Maurizio, Delprat, Christine, Henter, Jan-Inge, Svensson, Mattias
Format: Article en ligne
Langue:English
Publié: 2014
Accès à la collection:Clinical immunology (Orlando, Fla.)
Sujets:Journal Article Research Support, Non-U.S. Gov't Interleukin-17A; Langerhans cell histiocytosis; Monocytes; Retinoic acid orphan receptor C Retinoic acid orphan receptor γt; Interleukin-17 Lipopolysaccharide Receptors Nuclear Receptor Subfamily 1, Group F, Member 3
Description
Résumé:Copyright © 2014 Elsevier Inc. All rights reserved.
Langerhans cell histiocytosis (LCH) is a rare disease of unknown cause with manifestations ranging from isolated granulomatous lesions to life-threatening multi-system organ involvement. This disorder is further characterized by infiltration of immune cells in affected tissues and an association with interleukin (IL)-17A has been reported. Here, we investigated the presence of IL-17A-producing cells among peripheral blood mononuclear cells isolated from LCH patients and observed a high percentage of IL-17A(+) monocytes in peripheral blood of LCH patients compared to controls. The IL-17A(+) monocytes were also positive for the transcription factor retinoic acid orphan receptor (ROR) γt and showed increased mRNA levels for both IL-17A and RORγt. Notably, IL-17A was produced by all monocyte subsets and the expression level was positively associated with LCH disease activity. These data support a role for monocytes in the pathogenesis of LCH. Future therapeutic approaches may consider identification of patients who may benefit from IL-17A-targeted interventions
Description:Date Completed 12.09.2014
Date Revised 16.11.2017
published: Print-Electronic
Citation Status MEDLINE
ISSN:1521-7035
DOI:10.1016/j.clim.2014.04.004